NORTHLAND(BJ:430047)2025-02-24 09:15Financial Performance - The company achieved operating revenue of ¥72,110,862.43, an increase of 20.84% compared to the previous year[4] - The net profit attributable to shareholders was -¥45,180,740.62, with a basic earnings per share of -¥0.17[5] Assets and Equity - Total assets at the end of the reporting period were ¥477,534,006.34, reflecting a year-on-year increase of 45.54%[5] - Shareholders' equity attributable to the company increased by 116.33% to ¥331,442,284.06[5] - The company’s net asset per share attributable to shareholders rose by 105.08% to ¥1.21[5] Research and Development - The company is still in the R&D phase for its biopharmaceutical projects, which has resulted in continued losses[6] - The increase in total assets and equity is partly due to funds raised from a specific stock issuance[6] Financial Risks - The financial data presented is preliminary and has not been audited, highlighting potential investment risks[7]